MCID: NRC002
MIFTS: 63

Narcolepsy

Categories: Rare diseases, Neuronal diseases, Mental diseases, Genetic diseases

Aliases & Classifications for Narcolepsy

MalaCards integrated aliases for Narcolepsy:

Name: Narcolepsy 12 76 53 25 54 37 55 44 15 63 73
Narcolepsy-Cataplexy Syndrome 53 59 73
Cataplexy and Narcolepsy 29 6
Narcoleptic Syndrome 53 25
Gelineau Syndrome 53 25
Paroxysmal Sleep 12 53
Narcolepsy, Without Cataplexy 12
Narcolepsy Without Cataplexy 59
Gelineau's Syndrome 53
Gélineau Disease 59

Characteristics:

Orphanet epidemiological data:

59
narcolepsy-cataplexy syndrome
Prevalence: 1-5/10000 (Europe),1-5/10000 (Norway),1-5/10000 (Finland),1-5/10000 (China); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy;
narcolepsy without cataplexy
Prevalence: 1-5/10000 (United States); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:8986
ICD9CM 35 347.0
MeSH 44 D009290
NCIt 50 C84489
ICD10 via Orphanet 34 G47.4
MESH via Orphanet 45 D009290
UMLS via Orphanet 74 C0027404 C0751362
KEGG 37 H01293

Summaries for Narcolepsy

NINDS : 54 Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles. Many people with narcolepsy also experience uneven and interrupted sleep that can involve waking up frequently during the night.  At various times throughout the day, people with narcolepsy experience overpowering bouts of sleep. If the urge becomes overwhelming, individuals will fall asleep for periods lasting from a few seconds to several minutes. In rare cases, some people may remain asleep for an hour or longer.  In addition to excessive daytime sleepiness (EDS), people with narcolepsy experience some or all of the typical symptoms of cataplexy (the sudden loss of voluntary muscle tone), vivid hallucinations during sleep onset or upon awakening, and brief episodes of total paralysis at the beginning or end of sleep called sleep paralysis).  Because narcolepsy is often misdiagnosed as other conditions, it may take years to get the proper diagnosis. The cause of narcolepsy remains unknown.  It is likely that narcolepsy involves multiple factors interacting to cause neurological dysfunction and sleep disturbances.

MalaCards based summary : Narcolepsy, also known as narcolepsy-cataplexy syndrome, is related to cerebellar ataxia, deafness, and narcolepsy, autosomal dominant and idiopathic hypersomnia, and has symptoms including hemiplegia, sleep disturbances and snoring. An important gene associated with Narcolepsy is PICSAR (P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA
Association identified by GWAS.
Dysfunction Pattern: Mutation), and among its related pathways/superpathways are Th17 cell differentiation and HTLV-I infection. The drugs Dopamine and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related phenotypes are abnormality of vision and hallucinations

Disease Ontology : 12 A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work.

Genetics Home Reference : 25 Narcolepsy is a chronic sleep disorder that disrupts the normal sleep-wake cycle. Although this condition can appear at any age, it most often begins in adolescence.

NIH Rare Diseases : 53 Narcolepsy is a chronic brain disorder that involves poor control of sleep-wake cycles. People with narcolepsy have episodes of extreme daytime sleepiness and sudden, irresistible bouts of sleep (called "sleep attacks") that can occur at any time, and may last from seconds or minutes. Other signs and symptoms may include cataplexy (a sudden loss of muscle tone that makes a person go limp or unable to move); vivid dream-like images or hallucinations; and/or total paralysis just before falling asleep or after waking-up. Narcolepsy may have several causes, the most common being low levels of the neurotransmitter hypocretin (for various possible reasons). The disorder is usually sporadic but some cases are familial. There is no cure, but some symptoms can be managed with medicines and lifestyle changes.

PubMed Health : 63 About narcolepsy: Narcolepsy (NAR-ko-lep-se) is a disorder that causes periods of extreme daytime sleepiness. The disorder also may cause muscle weakness.Most people who have narcolepsy have trouble sleeping at night. Some people who have the disorder fall asleep suddenly, even if they're in the middle of talking, eating, or another activity.Narcolepsy also can cause:

Wikipedia : 76 Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake... more...

Related Diseases for Narcolepsy

Diseases in the Narcolepsy family:

Narcolepsy 1 Narcolepsy 2
Narcolepsy 3 Narcolepsy 4
Narcolepsy 5 Narcolepsy 6
Narcolepsy 7

Diseases related to Narcolepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 132)
# Related Disease Score Top Affiliating Genes
1 cerebellar ataxia, deafness, and narcolepsy, autosomal dominant 35.6 DNMT1 HCRT
2 idiopathic hypersomnia 34.3 HCRT HLA-DQB1
3 hypersomnia 34.0 HCRT HLA-DQB1 HLA-DRB1
4 sleep disorder 33.8 HCRT HCRTR1 HCRTR2 MOG
5 neuromyelitis optica 31.6 HCRT HLA-DRB1 MOG
6 acute disseminated encephalomyelitis 31.4 HCRT HLA-DQB1 HLA-DRB1 MOG
7 autoimmune disease 31.2 HLA-DQA1 HLA-DQB1 HLA-DRB1 MOG TNF
8 celiac disease 1 31.0 HLA-DQA1 HLA-DQB1 TNF
9 narcolepsy 1 12.5
10 narcolepsy 7 12.3
11 narcolepsy 2 12.1
12 narcolepsy 4 12.0
13 narcolepsy 5 12.0
14 narcolepsy 3 11.9
15 narcolepsy 6 11.9
16 disseminated sclerosis with narcolepsy 11.8
17 limbic encephalitis with lgi1 antibodies 11.3 HLA-DQB1 HLA-DRB1
18 beryllium disease 11.3 HLA-DQB1 HLA-DRB1 TNF
19 achalasia, familial esophageal 11.3 HLA-DQA1 HLA-DQB1
20 pediatric multiple sclerosis 11.3 HLA-DQB1 HLA-DRB1 MOG
21 focal epithelial hyperplasia 11.3 HLA-DQA1 HLA-DQB1 HLA-DRB1
22 autoimmune pancreatitis 11.3 HLA-DQB1 HLA-DRB1 TNF
23 chronic beryllium disease 11.3 HLA-DQB1 HLA-DRB1 TNF
24 rohhad 11.3 HCRT HCRTR1 HCRTR2
25 lichen sclerosus 11.3 HLA-DQB1 HLA-DRB1 TNF
26 recurrent respiratory papillomatosis 11.3 HLA-DQA1 HLA-DQB1 HLA-DRB1
27 endometritis 11.3 HLA-DQA1 HLA-DQB1 TNF
28 rubella 11.3 HLA-DQB1 HLA-DRB1 MOG TNF
29 panuveitis 11.3 HLA-DQB1 HLA-DRB1 TNF
30 recurrent hypersomnia 11.3 HCRT HLA-DQB1
31 idiopathic bronchiectasis 11.3 HLA-DQA1 HLA-DQB1 HLA-DRB1
32 sympathetic ophthalmia 11.3 HLA-DQA1 HLA-DRB1 TNF
33 geographic tongue 11.3 HLA-DQB1 HLA-DRB1 TNF
34 oligoarticular juvenile idiopathic arthritis 11.3 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
35 guillain-barre syndrome 11.3 HCRT HLA-DQB1 TNF
36 severe hemophilia a 11.3 HLA-DQB1 HLA-DRB1 TNF
37 metal allergy 11.2 HLA-DQB1 HLA-DRB1
38 optic neuritis 11.2 HLA-DRB1 MOG TNF
39 leishmaniasis 11.2 HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF
40 lichen planopilaris 11.2 HLA-DQB1 HLA-DRB1
41 rheumatic heart disease 11.2 HLA-DQA1 HLA-DRB1 TNF
42 toxoplasmosis 11.2 HLA-DQA1 HLA-DQB1 TNF
43 microscopic polyangiitis 11.2 HLA-DRB1 TNF
44 vogt-koyanagi-harada disease 11.2 HLA-DQA1 HLA-DQB1 HLA-DRB1
45 type ii mixed cryoglobulinemia 11.2 HLA-DQB1 HLA-DRB1
46 graft-versus-host disease 11.2 HLA-DQB1 HLA-DRB1 TNF
47 juvenile rheumatoid arthritis 11.2 HLA-DQA1 HLA-DRB1 TNF
48 idiopathic inflammatory myopathy 11.2 HLA-DQA1 HLA-DRB1
49 anca-associated vasculitis 11.1 HLA-DRB1 TNF
50 hallucinogen dependence 11.1 HCRTR1 HCRTR2

Comorbidity relations with Narcolepsy via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism

Graphical network of the top 20 diseases related to Narcolepsy:



Diseases related to Narcolepsy

Symptoms & Phenotypes for Narcolepsy

Human phenotypes related to Narcolepsy:

59 32 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of vision 59 32 frequent (33%) Frequent (79-30%) HP:0000504
2 hallucinations 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0000738
3 syncope 59 32 occasional (7.5%) Occasional (29-5%) HP:0001279
4 slurred speech 59 32 occasional (7.5%) Occasional (29-5%) HP:0001350
5 obesity 59 32 occasional (7.5%) Occasional (29-5%) HP:0001513
6 excessive daytime sleepiness 59 32 hallmark (90%) Very frequent (99-80%) HP:0002189
7 abnormal rapid eye movement sleep 59 32 frequent (33%) Frequent (79-30%) HP:0002494
8 cataplexy 59 32 hallmark (90%) Very frequent (99-80%) HP:0002524
9 transient global amnesia 59 32 hallmark (90%) Very frequent (99-80%) HP:0010534
10 excessive daytime somnolence 59 32 hallmark (90%) Very frequent (99-80%) HP:0001262
11 insomnia 59 32 hallmark (90%) Very frequent (99-80%) HP:0100785
12 abnormality of the eye 59 Frequent (79-30%)
13 sleep disturbance 59 Very frequent (99-80%),Very frequent (99-80%)
14 behavioral abnormality 59 Occasional (29-5%)

UMLS symptoms related to Narcolepsy:


hemiplegia, sleep disturbances, snoring, excessive daytime somnolence, sleeplessness, sluggishness

Drugs & Therapeutics for Narcolepsy

PubMedHealth treatment related to Narcolepsy: 63

Narcolepsy has no cure. However, medicines, lifestyle changes, and other therapies can relieve many of its symptoms. Treatment for narcolepsy is based on the type of symptoms you have and how severe they are.Not all medicines and lifestyle changes work for everyone. It may take weeks to months for you and your doctor to find the best treatment.

Drugs for Narcolepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68693-11-8 4236
3
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112111-43-0
4
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
5
Sodium oxybate Approved Phase 4,Phase 3,Phase 2,Phase 1 502-85-2 5360545
6
Ribavirin Approved Phase 4 36791-04-5 37542
7
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
8
Rasagiline Approved Phase 4 136236-51-6 3052776
9 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
10 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Wakefulness-Promoting Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antiparkinson Agents Phase 4,Not Applicable
18 calcium channel blockers Phase 4
19 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1
22 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1
23 Tranquilizing Agents Phase 4,Not Applicable
24 Anti-Anxiety Agents Phase 4,Not Applicable
25 Pharmaceutical Solutions Phase 4,Phase 3
26 Excitatory Amino Acid Antagonists Phase 4
27 Excitatory Amino Acids Phase 4
28 Anticonvulsants Phase 4
29 Protective Agents Phase 4,Phase 1,Phase 2
30 Psychotropic Drugs Phase 4,Not Applicable
31 Antimanic Agents Phase 4
32 Autonomic Agents Phase 4,Phase 2,Phase 1
33 Calcium, Dietary Phase 4,Phase 1,Phase 2
34 interferons Phase 4
35 Dopamine agonists Phase 4
36 Monoamine Oxidase Inhibitors Phase 4
37 Neuroprotective Agents Phase 4
38 Interferon-alpha Phase 4
39 Antioxidants Phase 4
40
Morphine Approved, Investigational Phase 3 57-27-2 5288826
41
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
42
Methylphenidate Approved, Investigational Phase 2, Phase 3,Not Applicable 113-45-1 4158
43
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
44
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
46 Narcotics Phase 3
47 Analgesics, Opioid Phase 3
48
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
49 Micronutrients Phase 3
50 Histamine H3 Antagonists Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
2 Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS Completed NCT00118378 Phase 4 Modafinil;Placebo
3 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
4 Pain Expectations in Subjects With Osteoarthritis Completed NCT02155257 Phase 4 Modafinil;Gabapentin;Placebo
5 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
6 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4 Sodium Oxybate
7 Xyrem and Brain Dopamine in Narcolepsy Recruiting NCT02637076 Phase 4 Xyrem
8 Modafinil Treatment for Sleep/Wake Disturbances in Older Adults Terminated NCT00626210 Phase 4 modafinil
9 Armodafinil for Patients Starting Hepatitis C Virus Treatment Terminated NCT01470651 Phase 4 Armodafinil;Sugar Pill
10 Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease Terminated NCT01048229 Phase 4 Rasagiline;Pramipexole
11 Palliative Morphine With or Without Concurrent Modafinil Unknown status NCT01766323 Phase 3 Modafinil;Placebo
12 Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
13 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT00107796 Phase 3 Modafinil
14 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" Completed NCT02348593 Phase 3 JZP-110
15 Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3 Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo)
16 PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107848 Phase 3 Modafinil
17 Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy Completed NCT00132873 Phase 3 Xyrem (sodium oxybate) oral solution
18 Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy Completed NCT00078377 Phase 3 Armodafinil;Armodafinil;Placebo
19 Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) Completed NCT01399606 Phase 3 BF2.649
20 Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness Completed NCT00214968 Phase 3 Modafinil
21 "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" Completed NCT02348632 Phase 3 JZP-110
22 Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
23 Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder Completed NCT00078312 Phase 3 CEP-10953 (Armodafinil)
24 Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients Completed NCT00049803 Phase 3 sodium oxybate
25 Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01067222 Phase 3 BF2.649;Modafinil;Placebo
26 Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
27 Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy Completed NCT01067235 Phase 3 BF2.649;BF2.649 add on Modafinil
28 Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) Completed NCT01789398 Phase 3 BF2.649
29 Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) Completed NCT01800045 Phase 3 Pitolisant;Placebo
30 Methylphenidate to Improve Balance and Walking in MS Completed NCT01896700 Phase 2, Phase 3 Methylphenidate;Placebo
31 Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients Completed NCT02478580 Phase 3 Nuvigil;Placebo
32 Modafinil in Cancer Related Fatigue Completed NCT01440621 Phase 3 Modafinil;Pyridoxine
33 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Completed NCT02348606 Phase 3 JZP-110
34 Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Recruiting NCT02720744 Phase 3 Sodium Oxybate;Placebo
35 A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Recruiting NCT03030599 Phase 3 JZP-258
36 A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy Active, not recruiting NCT02221869 Phase 3 Xyrem
37 Modafinil to Treat Fatigue in Post-Polio Syndrome Terminated NCT00067496 Phase 3 Modafinil
38 A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy Completed NCT00424931 Phase 2 JNJ-17216498;JNJ-17216498;Modafinil
39 A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy Completed NCT01681121 Phase 2 ADX-N05;Placebo
40 A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy Completed NCT01006122 Phase 2 Placebo;PF-03654746
41 A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness Completed NCT01485770 Phase 2 ADX-N05;Placebo
42 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
43 Flumazenil for the Treatment of Primary Hypersomnia Completed NCT01183312 Phase 1, Phase 2 Flumazenil
44 Methylphenidate and Parkinson's Disease Completed NCT00359723 Phase 2 methylphenidate
45 Sodium Oxybate in Schizophrenia With Insomnia Completed NCT00594256 Phase 2 Sodium Oxybate
46 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2 NRP104
47 Modafinil vs Placebo for the Treatment of Methamphetamine Dependence Completed NCT00469508 Phase 2 Modafinil;Placebo
48 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
49 Modafinil as an Adjunctive on Cognitive Functioning in Patients With Schizophrenia Completed NCT00314639 Phase 1, Phase 2 modafinil
50 A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy Recruiting NCT03267303 Phase 2 TS-091 5mg;TS-091 10mg;Placebo

Search NIH Clinical Center for Narcolepsy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: narcolepsy

Genetic Tests for Narcolepsy

Genetic tests related to Narcolepsy:

# Genetic test Affiliating Genes
1 Cataplexy and Narcolepsy 29

Anatomical Context for Narcolepsy

MalaCards organs/tissues related to Narcolepsy:

41
Brain, Eye, Testes, Heart, T Cells, Amygdala, Skin

Publications for Narcolepsy

Articles related to Narcolepsy:

(show top 50) (show all 903)
# Title Authors Year
1
Multiple sleep latency test in narcolepsy type 1 and narcolepsy type 2: A 5-year follow-up study. ( 29845680 )
2018
2
An overview of hypocretin based therapy in narcolepsy. ( 29623725 )
2018
3
Off-label Sodium Oxybate in Childhood Narcolepsy: A Comprehensive Report. ( 29942729 )
2018
4
Pseudotumor cerebri syndrome in a patient with narcolepsy type 1. ( 29195824 )
2018
5
Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States. ( 29910845 )
2018
6
Nocturnal REM Sleep Without Atonia Is a Diagnostic Biomarker of Pediatric Narcolepsy. ( 29351827 )
2018
7
Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy. ( 29784823 )
2018
8
Leg Movement Activity during Sleep in School-Age Children and Adolescents: A Detailed Study in Normal Controls and Subjects with Restless Legs Syndrome and Narcolepsy Type 1. ( 29365206 )
2018
9
The MSLT is Repeatable in Narcolepsy Type 1 But Not Narcolepsy Type 2: A Retrospective Patient Study. ( 29198301 )
2018
10
Modafinil Reduces Parasympathetic Activity but Does Not Influence Autonomic Reactivity to Orthostatic Load in Narcolepsy Type 1. ( 29901476 )
2018
11
Prostaglandin D2 Receptor DP1 Antibodies Predict Vaccine-induced and Spontaneous Narcolepsy Type 1: Large-scale Study of Antibody Profiling. ( 29449194 )
2018
12
An Epigenome-wide Association Study of DNA Methylation and An Integrated Genetic and Epigenetic Approach for Narcolepsy. ( 29425374 )
2018
13
Anesthetic Management of Narcolepsy Patients During Surgery: A Systematic Review. ( 29257771 )
2018
14
Impact of acute administration of sodium oxybate on heart rate variability in children with type 1 narcolepsy. ( 29880141 )
2018
15
Functional brown adipose tissue and sympathetic activity after cold exposure in humans with type 1 narcolepsy. ( 29771387 )
2018
16
Cyclic hypersomnolence with symptoms of narcolepsy with cataplexy: An unusual presentation of probable immune-mediated encephalitis. ( 29736425 )
2018
17
Remitting Narcolepsy? Longitudinal Observations in a Hypocretin-deficient Cohort. ( 29868885 )
2018
18
Associations Between Neuropsychological, Neurobehavioral and Emotional Functioning and Either Narcolepsy or Idiopathic Hypersomnia in Children and Adolescents. ( 29609710 )
2018
19
Narcolepsy Associated with Pandemrix Vaccine. ( 29855798 )
2018
20
Narcolepsy and Hypothalamic Region Tumors: Presentation and Evolution. ( 29909138 )
2018
21
Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. ( 29950444 )
2018
22
Drugs Used in Narcolepsy and Other Hypersomnias. ( 29759269 )
2018
23
Narcolepsy, brain imaging, and cognition: Understanding the connections. ( 29686129 )
2018
24
Narcolepsy with cataplexy and hyperthyroidism sudden appeared after H1N1 vaccination. ( 29796199 )
2018
25
Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. ( 29321233 )
2018
26
Chronic pain in narcolepsy type 1 and type 2 - an underestimated reality. ( 29923259 )
2018
27
The Association of Schizophrenia and Narcolepsy in Adolescents. ( 29622485 )
2018
28
Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis : Six new cases and a literature review. ( 29974206 )
2018
29
Two cases of childhood narcolepsy mimicking epileptic seizures in video-EEG/EMG. ( 29885874 )
2018
30
Update on the treatment of narcolepsy: clinical efficacy of pitolisant. ( 28490912 )
2017
31
Perioperative risks of narcolepsy in patients undergoing general anesthesia: A case-control study. ( 28433385 )
2017
32
Pharmacological management of narcolepsy with and without cataplexy. ( 28443381 )
2017
33
Treatment of narcolepsy and other organic hypersomnias in children. ( 28735675 )
2017
34
Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2A years of follow-up. ( 27995693 )
2017
35
Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. ( 28847694 )
2017
36
Adenotonsillectomy outcomes in children with sleep apnea and narcolepsy. ( 28802388 )
2017
37
[18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia. ( 28775709 )
2017
38
Sleep-wake patterns, non-rapid eye movement, and rapid eye movement sleep cycles in teenage narcolepsy. ( 28449905 )
2017
39
Diagnosis and Management of Narcolepsy. ( 28837992 )
2017
40
Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. ( 28507129 )
2017
41
Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. ( 29221779 )
2017
42
Criteria for gauging response to sodium oxybate for narcolepsy. ( 29205601 )
2017
43
Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. ( 28449892 )
2017
44
Rare missense mutations in P2RY11 in narcolepsy with cataplexy. ( 28460015 )
2017
45
Comorbidity of narcolepsy and depressive disorders: a nationwide population-based study in Taiwan. ( 29157595 )
2017
46
Comorbidity of narcolepsy with cataplexy and transverse myelitis: aA common autoimmune background? A case report. ( 28449899 )
2017
47
Antibody Affinity Against 2009 A/H1N1 Influenza and Pandemrix Vaccine Nucleoproteins Differs Between Childhood Narcolepsy Patients and Controls. ( 28796576 )
2017
48
Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment. ( 28940143 )
2017
49
Cortical and Subcortical Brain Changes in Children and Adolescents With Narcolepsy Type 1. ( 29244164 )
2017
50
Association Study of HLA-DQB1*0602 Allele in Iranian Patients with Narcolepsy. ( 29149785 )
2017

Variations for Narcolepsy

ClinVar genetic disease variations for Narcolepsy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PPAN NM_020230.6(PPAN): c.190-151C> T single nucleotide variant association rs1551570 GRCh38 Chromosome 19, 10107354: 10107354
2 PPAN NM_020230.6(PPAN): c.190-151C> T single nucleotide variant association rs1551570 GRCh37 Chromosome 19, 10218030: 10218030
3 P2RY11 NM_002566.4(P2RY11): c.-203A> G single nucleotide variant association rs12460842 GRCh38 Chromosome 19, 10111519: 10111519
4 P2RY11 NM_002566.4(P2RY11): c.-203A> G single nucleotide variant association rs12460842 GRCh37 Chromosome 19, 10222195: 10222195
5 P2RY11 NM_002566.4(P2RY11): c.*638G> A single nucleotide variant association rs2305795 GRCh38 Chromosome 19, 10115376: 10115376
6 P2RY11 NM_002566.4(P2RY11): c.*638G> A single nucleotide variant association rs2305795 GRCh37 Chromosome 19, 10226052: 10226052
7 EIF3G NM_003755.4(EIF3G): c.596-260T> C single nucleotide variant association rs3826784 GRCh38 Chromosome 19, 10116334: 10116334
8 EIF3G NM_003755.4(EIF3G): c.596-260T> C single nucleotide variant association rs3826784 GRCh37 Chromosome 19, 10227010: 10227010

Copy number variations for Narcolepsy from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 177309 3 55147029 55255377 Insertion HCRTR2 Narcolepsy

Expression for Narcolepsy

Search GEO for disease gene expression data for Narcolepsy.

Pathways for Narcolepsy

GO Terms for Narcolepsy

Cellular components related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.58 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 endocytic vesicle membrane GO:0030666 9.54 HLA-DQA1 HLA-DQB1 HLA-DRB1
3 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 transport vesicle membrane GO:0030658 9.43 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DQA1 HLA-DQB1 HLA-DRB1
7 MHC class II protein complex GO:0042613 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Biological processes related to Narcolepsy according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 T cell receptor signaling pathway GO:0050852 9.71 HLA-DQA1 HLA-DQB1 HLA-DRB1 MOG
2 neuropeptide signaling pathway GO:0007218 9.7 HCRT HCRTR1 HCRTR2
3 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.69 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 T cell costimulation GO:0031295 9.67 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 interferon-gamma-mediated signaling pathway GO:0060333 9.65 HLA-DQA1 HLA-DQB1 HLA-DRB1
6 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.63 HCRT HCRTR2 P2RY11
7 immune response GO:0006955 9.63 CTSH HLA-DQA1 HLA-DQB1 HLA-DRB1 TNF TNFSF4
8 response to peptide GO:1901652 9.54 HCRTR1 HCRTR2
9 feeding behavior GO:0007631 9.5 HCRT HCRTR1 HCRTR2
10 regulation of circadian sleep/wake cycle, sleep GO:0045187 9.43 HCRTR1 HCRTR2
11 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.37 HLA-DQB1 HLA-DRB1
12 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.26 HLA-DQB1 HLA-DRB1
13 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.13 HLA-DQA1 HLA-DQB1 HLA-DRB1
14 antigen processing and presentation GO:0019882 8.92 CTSH HLA-DQA1 HLA-DQB1 HLA-DRB1

Molecular functions related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 orexin receptor activity GO:0016499 8.96 HCRTR1 HCRTR2
3 MHC class II receptor activity GO:0032395 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Sources for Narcolepsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....